Ranbaxy Pharmaceuticals, Princeton, N.J., a wholly owned subsidiary of Ranbaxy Laboratories Ltd., received FDA approval for acetaminophen and codeine phosphate tablets USP, 300 mg/30 mg and 300 mg/60 mg.
The products are AA rated and therapeutically equivalent to Tylenol with Codeine tablets USP, No. 3 and No. 4, respectively. Acetaminophen and codeine phosphate tablets are indicated for the relief of mild to moderately severe pain. The final dosage form will be manufactured and packaged at Core Pharma LLC, Middlesex, N.J., and marketed through the Ranbaxy’s sales and marketing organization.